Wave Life Sciences Pte Ltd
Wave Life Sciences Pte Ltd is listed today as Wave Life Sciences Ltd.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2015 | $66 M | No. 2 | $50 to $250 million | equity | SEC | |
| Jan 2015 | $12 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Wave Life Sciences Pte Ltd chose not to state its revenue in its newest notice of a funding round (Aug 2015).
SEC Form D · Aug 2015
The industry group it chose in its notices: Other Health Care.
SEC Form D · Aug 2015
That is all the official record says: Wave Life Sciences Pte Ltd has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Wave Life Sciences Pte Ltd are on record.
Investors#
4 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Kagoshima Shinsangyo Sousei Investment Limited Partnership | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| RA Capital Healthcare Fund LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2015) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2015) | SEC Form 3 |
| Shin Nippon Biomedical Laboratories, Ltd. | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 19 investors.
Largest shareholders today
Institutions holding Wave Life Sciences Ltd. shares, as of Sep 30, 2026.
- Ra Capital Management, L.P.$100 M13.68%
- BlackRock, Inc.$78 M10.69%
- GSK plc$68 M9.25%
- Maverick Capital LTD$36 M4.93%
- Two Sigma Investments, LP$22 M2.99%
- State Street Corp$21 M2.87%
- Readystate Asset Management LP$20 M2.81%
- 683 Capital Management, LLC$20 M2.77%
- Primecap Management Co/ca/$19 M2.60%
- M28 Capital Management LP$17 M2.33%
- FMR LLC$14 M1.94%
- Qube Research & Technologies Ltd$14 M1.86%
- Marshall Wace, LLP$14 M1.86%
- Geode Capital Management, LLC$13 M1.78%
- UBS Group AG$11 M1.47%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Paul B. Bolno, M.D. | Executive officer | Aug 2015 |
| Tan Ping Ping | Executive officer | Aug 2015 |
| Gregory L. Verdine | Director | Aug 2015 |
| Ken L. Takanashi | Director | Aug 2015 |
| Koji L. Miura | Director | Aug 2015 |
| Masaharu L. Tanaka | Director | Aug 2015 |
| Paul B. Bolno, M.D. | Director | Aug 2015 |
| Peter L. Kolchinsky | Director | Aug 2015 |
| Takeshi L. Wada | Director | Aug 2015 |
About
Biotechnology company.
Went public since 2015. Its SEC number is that of a company listed on a stock exchange.